[HTML][HTML] Constant BCR-ABL transcript level≥ 0.1%(IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis
KM Poláková, V Polívková, J Rulcová, H Klamová… - Experimental …, 2010 - Elsevier
OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …
cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at≥ 0.1% level in a …
Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
NCP Cross, HE White, PAS Evans… - British journal of …, 2018 - Wiley Online Library
For patients with chronic myeloid leukaemia (CML), treatment guidelines recommend
monitoring response to treatment with tyrosine kinase inhibitors (TKI s) by testing the BCR …
monitoring response to treatment with tyrosine kinase inhibitors (TKI s) by testing the BCR …
Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?
M Norkin, CA Schiffer - Current hematologic malignancy reports, 2010 - Springer
Monitoring of disease response during treatment with tyrosine kinase inhibitors of patients
with chronic myelogenous leukemia dramatically changed after the introduction of real-time …
with chronic myelogenous leukemia dramatically changed after the introduction of real-time …
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase
M Lauseker, B Hanfstein, C Haferlach… - Journal of cancer …, 2014 - Springer
Purpose Chronic myeloid leukemia (CML) patients are monitored by both cytogenetic and
molecular assessments, although present guidelines appear to switch from cytogenetic to …
molecular assessments, although present guidelines appear to switch from cytogenetic to …
[PDF][PDF] Tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia: a retrospective analysis of 208 Italian patients
C Fava, G Rege Cambrin, I Dogliotti, P Berchialla… - Haematologica, 2016 - arpi.unipi.it
Methods: As with the WHO panel, the secondary panel was manufactured by lyophilizing K-
562 and HL-60 cell mixtures. Reverse-transcription droplet digital polymerase chain reaction …
562 and HL-60 cell mixtures. Reverse-transcription droplet digital polymerase chain reaction …
[HTML][HTML] Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients
G Martinelli, I Iacobucci, G Rosti, F Pane, M Amabile… - Annals of oncology, 2006 - Elsevier
Abstract Imatinib mesylate (STI571), a specific Bcr-Abl inhibitor, has shown a potent
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
antileukemic activity in clinical studies of chronic myeloid leukemia (CML) patients. Early …
Determination of BCR-ABL Overexpression by Correlating qRT-PCR and IP-FISH in Imatinib Treated CML Patients.
M Bianchini, P Gargallo, F Alú, P Barreyro, B Rosales… - Blood, 2007 - Elsevier
Imatinib mesylate (IM) has proven to be the most effective treatment in Chronic Myeloid
Leukemia (CML). Nevertheless, IM resistance and molecular evidence of persistent disease …
Leukemia (CML). Nevertheless, IM resistance and molecular evidence of persistent disease …
[HTML][HTML] Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
IC Haznedaroglu - … journal of hematology and infectious diseases, 2014 - ncbi.nlm.nih.gov
The aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is
to get ideal hematological, cytogenetic, molecular responses at the critical time points. The …
to get ideal hematological, cytogenetic, molecular responses at the critical time points. The …
Comparison of" Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients.
P Paschka, S Branford, C Lorentz, R Hehlmann… - Blood, 2004 - Elsevier
During the last decade, several studies have shown that quantification of residual tumor
cells significantly correlates with clinical outcome in chronic myelogenous leukemia (CML) …
cells significantly correlates with clinical outcome in chronic myelogenous leukemia (CML) …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …